Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa

NCT ID: NCT02021318 Phase: PHASE3 Status: COMPLETED Enrollment: 616 Completion: 2019-11-06

Conditions

Anemia in Chronic Kidney Disease in Non-dialysis Patients

Interventions

Roxadustat, Darbepoetin alfa

Summary

The primary objective of this study was to evaluate the efficacy of roxadustat compared to darbepoetin alfa in the treatment of anemia in nondialysis-dependent chronic kidney disease (NDD CKD) participants.

Primary Outcome

Percentage of Participants With a Hb Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy

Source

ClinicalTrials.gov